Latest News

Uncategorized

ESMO 2019: Patient-Reported Outcomes From TITAN in Patients with Metastatic Castration-Sensitive Prostate Cancer

Barcelona, Spain (UroToday.com) Androgen deprivation therapy (ADT) has long been considered the standard of care for patients with metastatic prostate cancer, however recent studies have shown improved survival outcomes by adding additional agents. In the TITAN study, compared with placebo, the addition of apalutamide to ADT significantly improved radiographic progression-free survival (rPFS; HR 0.48, 95% […]

Uncategorized

ESMO 2019: A First-in-Human Phase 1/2 Trial of the Oral HIF-2a Inhibitor PT2977 in Patients with Advanced RCC

Barcelona, Spain (UroToday.com) Hypoxia-inducible factor (HIF)-2α is a transcription factor that is a key oncogenic driver in renal cell carcinoma (RCC) attributed, in 80-90% of patients, to the underlying protein product of von Hippel-Lindau tumor suppressor gene deficiency.1 VHL gene inactivation leads to accumulation of HIF-2α, which heterodimerizes with HIF-1β and activates the transcription of genes associated […]

Uncategorized

ESMO 2019: Invited Discussant: Patient Reported Outcomes in Metastatic Hormone-Naïve Prostate Cancer and Who to Give Primary Radiotherapy To?

Barcelona, Spain (UroToday.com) At the prostate cancer poster discussion at ESMO 2019, Dr. Henrik Gronberg provided a discussion of three important abstracts: the updated STAMPEDE “M1|RT Comparison”, as well as patient reported outcomes from both ENZAMET and TITAN.  Dr. Gronberg notes that in the initial STAMPEDE “M1|RT Comparison” published last year, the STAMPEDE collaborators noted […]

Uncategorized

ESMO 2019: Patient-Reported Outcomes From TITAN: A Phase 3, Randomized, Double-Blind Study of Apalutamide Versus Placebo Added to Androgen Deprivation Therapy in Patients With Metastatic Castration-Sensitive Prostate Cancer

Barcelona, Spain (UroToday.com) The randomized, phase 3 TITAN evaluated the addition of apalutamide versus placebo to androgen deprivation therapy (ADT) in men with metastatic hormone-sensitive prostate cancer (mHSPC). Results from TITAN demonstrated that apalutamide plus ADT significantly improved overall survival and radiographic progression-free survival versus placebo plus ADT in men with mHSPC.1 This abstract presents […]

Uncategorized

ESMO 2019: FGFR3 Alteration as a Predictor of Non-Response to Neoadjuvant Pembrolizumab in Muscle-Invasive Bladder Cancer

Barcelona, Spain (UroToday.com) In the PURE-01 study, neoadjuvant pembrolizumab resulted in a 42% pT0 rate and 54% pathological downstaging rate in patients with muscle-invasive bladder cancer.1 Looking in more detail, pT0 patients had features suggesting pre-existing immunity or higher tumor mutational burden may promote response. At the ESMO 2019 annual congress, Dr. Necchi and colleagues […]

Uncategorized

ESMO 2019: Exploratory Analyses of Metastatic Site and Number in the STAMPEDE “M1|RT Comparison”

Barcelona, Spain (UroToday.com)  Prostate radiotherapy with androgen deprivation therapy (ADT) is now recommended as a first line option for de-novo low burden metastatic prostate cancer. In the STAMPEDE “M1|RT comparison” metastatic burden was a determinant of benefit, based on pre-specified prognostic criteria.1 However, the pre-specified metastatic burden criteria used to dichotomize was based on prognostic […]

Uncategorized

ESMO 2019: Diagnosis, Management, and Burden of Renal Cell Carcinomas: Results from a Global Patient Survey in 43 Countries

Barcelona, Spain (UroToday.com)  The International Kidney Cancer Coalition (IKCC) is a federation of 45 affiliated patient organizations representing 1.2 million patients worldwide that is committed to reduce the global burden of kidney cancer. To date, a large-scale global survey of RCC patients to capture real world experiences among clinicians and patients has never been undertaken. […]

Uncategorized

ESMO 2019: Central, Prospective Detection of Homologous Recombination Repair Gene Mutations (HRRm) in Tumour Tissue from >4000 Men with mCRPC Screened for the PROfound Study

Barcelona, Spain (UroToday.com) A significant proportion of patients with metastatic prostate cancer have tumor cells harboring germline and/or somatic homologous recombination repair (HRR) gene alterations. Alterations in HRR genes such as BRCA1, BRCA2, and others are recognized to confer sensitivity to PARP inhibitors to varying extents. The PROfound study (NCT02987543) is the first positive Phase 3, […]

Uncategorized

ESMO 2019: Introduction to Genomic Tumor Board Educational Session

Barcelona, Spain (UroToday.com) To introduce this educational session on precision medicine, Dr. Rubin highlighted the multifaceted nature of precision medicine. Precision medicine efforts must incorporate “big data” such as genomic data, which can consist of DNA and RNA-derived information from a large population, small data such as electronic health records and patient reported data, and […]

Uncategorized

ESMO 2019: Health-Related Quality of Life in a Randomized Phase 3 Trial of Enzalutamide with Standard First Line Therapy for Metastatic Hormone-Sensitive Prostate Cancer: ENZAMET, ANZUP-led, International, Co-Operative Group Trial

Barcelona, Spain (UroToday.com)  At 2019 ASCO meeting, Davis and colleagues previously reported that treatment with enzalutamide rather than an older non-steroidal anti-androgen (bicalutamide, nilutamide, or flutamide), resulted in longer overall survival when added to standard first-line treatment, with or without concurrent early docetaxel, in mHSPC (HR 0.67, 95% CI 0.52 to 0.86, p = 0.002).1 Additionally, enzalutamide […]

X